Aspen Neuroscience

Edit info

Founded: 2018

Location: San Diego, CA

Employee range: 11 - 50

Clinical stage: Clin0

Therapy area: Idiopathic Parkinson's

Drug types: NEU, GEN

Lead product: ANPD001

Funding: $147.5M B May 2022; $70M A Mar 2020; $6.5M Dec 2019

aspenneuroscience.com

linkedin.com

job board

Drug notes:

ANDP002 RD genetic Parkinson's

About:

Aspen Neuroscience is combining stem cell biology with genomics to create therapies to treat patients with neurodegenerative diseases. Parkinson’s Disease is the second most common neurodegenerative disease with no disease-modifying agents available. Since patients lose ~50% of dopamine neurons, cell replacement therapy has the potential to restore function. Using their stem cell biology and genomics platform, Aspen is providing the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson’s Disease. This regenerative therapy for Parkinson’s Disease uses the patient's own cells and avoids the need for immunosuppression and is currently undergoing investigational new drug-enabling studies.